Open AccessPhase III, Placebo-Controlled Trial of Three Doses of Citalopram for the Treatment of Hot Flashes: NCCTG Trial N05C9
Author(s) -
Debra L. Barton,
Beth LaVasseur,
Jeff A. Sloan,
Allen N. Stawis,
Kathleen Flynn,
Missy Dyar,
David B. Johnson,
Philip J. Atherton,
Brent Diekmann,
Charles L. Loprinzi
Publication year - 2010
Publication title -
journal of clinical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 10.482
H-Index - 548
eISSN - 1527-7755
pISSN - 0732-183X
DOI - 10.1200/jco.2009.26.6379
Subject(s) - citalopram , hot flash , medicine , placebo , randomized controlled trial , clinical endpoint , adverse effect , anesthesia , serotonin , cancer , alternative medicine , receptor , pathology , breast cancer
Up to 75% of women experience hot flashes, which can negatively impact quality of life. As hot flash physiology is not definitively understood, it cannot be assumed that effective agents represent class effects. Therefore, there is a continued need for rigorous evaluation to identify effective nonhormonal options for hot flash relief.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom